6,720 reports of this reaction
3.3% of all OLANZAPINE reports
#2 most reported adverse reaction
WEIGHT INCREASED is the #2 most commonly reported adverse reaction for OLANZAPINE, manufactured by Eli Lilly and Company. There are 6,720 FDA adverse event reports linking OLANZAPINE to WEIGHT INCREASED. This represents approximately 3.3% of all 204,278 adverse event reports for this drug.
OLANZAPINE has an overall safety score of 88 out of 100. Patients taking OLANZAPINE who experience weight increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
WEIGHT INCREASED is moderately reported among OLANZAPINE users, representing a notable but not dominant share of adverse events.
In addition to weight increased, the following adverse reactions have been reported for OLANZAPINE:
The following drugs have also been linked to weight increased in FDA adverse event reports:
WEIGHT INCREASED has been reported as an adverse event in 6,720 FDA reports for OLANZAPINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
WEIGHT INCREASED accounts for approximately 3.3% of all adverse event reports for OLANZAPINE, making it one of the most commonly reported side effect.
If you experience weight increased while taking OLANZAPINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.